JPRN-UMIN000030548
Completed
未知
Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trial - Comparison of Dapagliflozin and Pioglitazone Effects on NAFLD and NASH in Patients With Type 2 Diabetes: A Randomized Trial
Conditionstype 2 diabetes mellitus, NAFLD, NASH
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- type 2 diabetes mellitus, NAFLD, NASH
- Sponsor
- Saitama Medical University Hospital
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with diabetes complications
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Comparison of Dapagliflozin and Pioglitazone for Non-Alcoholic Fatty Liver Disease in Type 2 DiabetesHealth Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2024/07/071087Babra
Recruiting
Phase 3
Effects of Dapagliflozin and Empagliflozin in Myocardial DysfunctioIRCT20111206008307N45Tabriz University of Medical Sciences75
Not yet recruiting
Phase 2
Comparing the effect of Empagliflozin, Pioglitazone and their combination, on the course of non-alcoholic fatty liver disease in diabetic patientson-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0IRCT20230903059343N1Arak University of Medical Sciences120
Recruiting
Phase 3
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsHealth Condition 1: E112- Type 2 diabetes mellitus with kidney complicationsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
Completed
Not Applicable
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340